Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

What This U.S. Milestone Signals for Orthocell’s (ASX:OCC) MedTech Expansion

The global regenerative medicine landscape continues to evolve rapidly, with innovative technologies transforming patient care and surgical outcomes. In a significant development, Orthocell Limited (ASX:OCC) has successfully completed the first surgical case using its nerve repair product, Remplir™, within the United States Department of …

Shwetambri Chauhan | 17 April 2026

Telix Pharmaceuticals (ASX:TLX) Analysis: Growth Trajectory, Pipeline Progress and Long-Term Investment Outlook

Telix Pharmaceuticals Ltd (ASX:TLX) has emerged as one of the more closely followed names within the biotechnology segment of the Australian Securities Exchange, reflecting its positioning at the intersection of precision medicine and oncology-focused radiopharmaceuticals. While biotechnology companies often face prolonged development timelines and …

Aditi Sarkar | 16 April 2026

Mesoblast (ASX:MSB) stock analysis: Transitioning to Commercial Growth with Ryoncil Momentum

Mesoblast Limited (ASX:MSB) has transitioned from a high-stakes clinical developer into a commercially viable leader in allogeneic cellular medicines. The share price of AUD 2.24 on 16 April 2026, reflects a year of significant recovery, with the stock up over 38% over the past …

Aditi Sarkar | 16 April 2026

Starpharma (ASX:SPL) Jumps Over 580% in a Year: What’s Behind the Rally?

Starpharma Holdings Ltd (ASX:SPL) has undergone a notable transformation in market positioning, with its share price rising more than 580% over the past year. The stock’s latest intraday gain of close to 10% reinforces a broader upward trajectory, with consistent gains recorded across weekly, …

Aditi Sarkar | 16 April 2026

From 700% Gains to Recent Declines: What’s Driving Lumos Diagnostics (ASX: LDX)?

Lumos Diagnostics Holdings Ltd (ASX: LDX) has experienced significant share price volatility, characterised by sharp long-term gains followed by a notable correction in recent months. The company’s trajectory reflects a shift from speculative re-rating toward a more execution-focused phase, where commercial progress and revenue …

Aditi Sarkar | 16 April 2026

Xenitra (ASX:XEN) Surges 33% as Q3 Sales Rocket 305%

Xenitra Limited (ASX:XEN) delivered the largest percentage gain in this analysis during morning trading on 16 April 2026, advancing $0.001 or 33.3% to $0.004 on volume of 5,805,328 shares. At sub-cent prices, even small absolute price movements represent large percentage changes, and the 33.3% …

Sonal Goyal | 16 April 2026

Botanix Pharmaceuticals (ASX:BOT) Surges 17% After Securing Second API Supplier Agreement for Qnol

Botanix Pharmaceuticals Limited (ASX:BOT) delivered one of the morning session's strongest percentage gains on 16 April 2026, advancing $0.006 or 16.7% to $0.042 on volume of 50,269,064 shares — the highest single-stock volume count in this analysis. The extraordinary share count reflects the company's …

Sonal Goyal | 16 April 2026

Pro Medicus (ASX:PME) Shares Climb as US Medical Imaging Momentum Accelerates

The company operates a business model centred on subscription licensing, with customers typically entering multi-year contracts. The platform is cloud-native, scalable, and increasingly integrated with artificial intelligence tools for diagnostic support, image analysis, and workflow enhancement. Pro Medicus derives revenue primarily from North America, …

Aditi Sarkar | 16 April 2026

Ansell (ASX:ANN): Volume Spike Reflects Institutional Appetite for Global Protective Equipment Leader

Ansell Ltd (ASX:ANN) is a global leader in protective gloves and personal protective equipment serving healthcare, industrial, automotive, food processing, and chemical sectors worldwide. The company manufactures latex and nitrile gloves, barrier protection solutions, chemical-resistant apparel, and specialty protective equipment. Manufacturing facilities and distribution …

Aditi Sarkar | 16 April 2026

BlinkLab (ASX:BB1) Secures Fresh Capital to Advance U.S. FDA Trials and European Expansion

BlinkLab Ltd (ASX:BB1) shares fell 3.18% to AUD 0.76 during the afternoon session on 16 April 2026, despite the company announcing a A$17.5 million capital raise. The stock remains up approximately 111.11% over the past year. Today’s decline in share price comes even as …

Aditi Sarkar | 16 April 2026
Support

Hi! How can we help you today?

Loading…